Scholarlink

<p>NT-proBNP levels increase exponentially with age and are associated with cardiovascular and all-cause mortality. From NT-proBNP concentration a surrogate for biological age (“proBNPage”) can be obtained. The primary objective of this study was to define a method to design future trials on anti-aging treatments using proBNPage. The secondary objective was the tentative evaluation of 4 potential anti-aging dietary supplements. The trial lasted 2&#xa0;years and involved 120 healthy subjects aged 71.7 ± 4.6&#xa0;years divided into 3 groups: A) coenzyme Q10 100&#xa0;mg bid + selenium 100 mcg, B) resveratrol 350&#xa0;mg bid + TA-65 100U, C) placebo. ProBNPage was the primary outcome variable. Secondary variables included step test duration, handgrip strength, and self-reported health status. In group B, the study was interrupted at month 5 due to significant LDL-cholesterol increase, probably caused by the high-dose resveratrol. Partly because of dropouts and inadequate treatment intake, groups A and C showed non-significant differences in the primary and secondary variables. Therefore, these groups were considered a single group, in which after 2&#xa0;years proBNPage increased by 2.5&#xa0;years (<i>P</i> = 0.01), particularly in subjects over 70 (+ 3.0&#xa0;years, <i>P</i> = 0.009). It was thus calculated that 126 subjects over 70 could allow the assessment of a 2-year treatment vs. placebo with a power of 80%. This study has developed an NT-proBNP-based method to evaluate future interventions on biological age. The treatments did not induce significant changes in proBNPage. The marked increase in cholesterol in group B suggests that high-dose resveratrol should be avoided.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The proBNPage reduction (PBAR) trial—results of a randomized, double blind, placebo-controlled, pilot study to fine tune an NT-proBNP-based method to assess the effect of anti-aging treatments

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月8日

查看全文
  • Antonio Muscari,
  • Paola Forti,
  • Donatella Magalotti,
  • Mara Brizi,
  • Filomena Piro,
  • Eric Ramazzotti,
  • Loredana Incorvaia,
  • Paolo Maltoni,
  • Daniele Casanova Borca,
  • Eleonora Capelli,
  • Barbara Ciuffi,
  • Paolo Pandolfi,
  • Giovanni Barbara

摘要

NT-proBNP levels increase exponentially with age and are associated with cardiovascular and all-cause mortality. From NT-proBNP concentration a surrogate for biological age (“proBNPage”) can be obtained. The primary objective of this study was to define a method to design future trials on anti-aging treatments using proBNPage. The secondary objective was the tentative evaluation of 4 potential anti-aging dietary supplements. The trial lasted 2 years and involved 120 healthy subjects aged 71.7 ± 4.6 years divided into 3 groups: A) coenzyme Q10 100 mg bid + selenium 100 mcg, B) resveratrol 350 mg bid + TA-65 100U, C) placebo. ProBNPage was the primary outcome variable. Secondary variables included step test duration, handgrip strength, and self-reported health status. In group B, the study was interrupted at month 5 due to significant LDL-cholesterol increase, probably caused by the high-dose resveratrol. Partly because of dropouts and inadequate treatment intake, groups A and C showed non-significant differences in the primary and secondary variables. Therefore, these groups were considered a single group, in which after 2 years proBNPage increased by 2.5 years (P = 0.01), particularly in subjects over 70 (+ 3.0 years, P = 0.009). It was thus calculated that 126 subjects over 70 could allow the assessment of a 2-year treatment vs. placebo with a power of 80%. This study has developed an NT-proBNP-based method to evaluate future interventions on biological age. The treatments did not induce significant changes in proBNPage. The marked increase in cholesterol in group B suggests that high-dose resveratrol should be avoided.